Rifaximin + rifaximin
Phase 1/2Completed 1 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Minimal Hepatic Encephalopathy
Conditions
Minimal Hepatic Encephalopathy
Trial Timeline
Feb 1, 2010 → Dec 1, 2012
NCT ID
NCT01069133About Rifaximin + rifaximin
Rifaximin + rifaximin is a phase 1/2 stage product being developed by Bausch Health for Minimal Hepatic Encephalopathy. The current trial status is completed. This product is registered under clinical trial identifier NCT01069133. Target conditions include Minimal Hepatic Encephalopathy.
Hype Score Breakdown
Clinical
9
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01069133 | Phase 1/2 | Completed |
Competing Products
4 competing products in Minimal Hepatic Encephalopathy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pudexacianinium chloride | Astellas Pharma | Phase 2 | 35 |
| Blinatumomab in combination with donor lymphocyte infusion | Amgen | Phase 2 | 27 |
| Clofarabine + Cytarabine intravenous + Methotrexate + Intrathecal (IT) Cytarabine | Sanofi | Phase 2 | 27 |
| Tislelizumab + Fruquintinib | Takeda Pharmaceutical | Phase 2 | 42 |